BIOGY Biogaia AB Forecast, Technical & Fundamental Analysis

BIOGY saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for BIOGY moved out of overbought territory on October 07, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 29 similar instances where the indicator exited the overbought zone. In of the 29 cases the stock moved lower. This puts the odds of a downward move at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

BIOGY broke above its upper Bollinger Band on September 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 16, 2025. You may want to consider a long position or call options on BIOGY as a result. In of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BIOGY just turned positive on September 16, 2025. Looking at past instances where BIOGY's MACD turned positive, the stock continued to rise in of 25 cases over the following month. The odds of a continued upward trend are .

BIOGY moved above its 50-day moving average on September 16, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BIOGY crossed bullishly above the 50-day moving average on September 23, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.251) is normal, around the industry mean (18.744). P/E Ratio (37.320) is within average values for comparable stocks, (73.784). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.989). BIOGY has a moderately high Dividend Yield (0.063) as compared to the industry average of (0.030). P/S Ratio (7.418) is also within normal values, averaging (47.108).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BIOGY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOGY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.